Optonol

Optonol Overview

Optonol's flagship product, Ex-Press, is a miniature surgical implant used to lower intra-ocular pressure in patients with glaucoma. Optonol was founded as a spin-off of Jerusalem-based stent developer Medinol Ltd. Optonol was acquired by Alcon in December 2009. A year later, Alcon was acquired by Novartis.

Cumulative Funding Raised Over Time ($)

Latest News

Dec 14, 2009 · www.globes.co.il

growth-positive

Alcon buys Israeli glaucoma treatment co Optonol

Israeli glaucoma treatment company Optonol Ltd. has been acquired by US eye care company Alcon in a deal potentially worth hundreds of millions of dollars. Optonol will receive an initial cash payment of $150 million for its Ex-Press mini-glaucoma shunt family of products. Milestone payments could earn the company hundreds of millions of dollars. Optonol was founded in 1996 and has raised $30 million in funding. The acquisition is expected to close by the end of the first quarter of 2010.

Acquisition

Funding

Team Members

3

Employees: 1-10

Web & Social Links

Locations

Neve Ilan, Israel

Photos & Videos

No files yet

Optonol Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info